SNPMiner Trials by Shray Alag

SNPMiner SNPMiner Trials (Home Page)

Report for Clinical Trial NCT03595644

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Maintenance Targeted Therapy With or Without Stereotactic Body Radiation Therapy for Stage IV Non-small Cell Lung Cancer: a Prospective, Multicenter, Randomized Controlled Clinical Trial.

This is a Prospective, Multicenter, Randomized Controlled study to evaluate Stereotactic Body Radiation Therapy (SBRT) as a potential treatment for stage IV non-small cell lung cancer (NSCLC) that has a mutated epidermal growth factor receptor (EGFR) and has been receiving treatment with a targeted agent such as gefitinib, erlotinib and icotinib.

NCT03595644 Stage IV Non-small Cell Lung Cancer
MeSH:Lung Neoplasms Carcinoma, Non-Small-Cell Lung
HPO:Neoplasm of the lung Non-small cell lung carcinoma

2 Interventions


Description: Received SBRT after three months after EGFR-TKI treatment
Type: Radiation
Group Labels: 1


Name: TKI

Description: Received EGFR-TKI treatment
Type: Drug
Group Labels: 1


Primary Outcomes

Description: progression-free survival

Measure: PFS

Time: 2 years

Secondary Outcomes

Description: overall survival

Measure: OS

Time: 3 year

Purpose: Treatment

Allocation: Randomized

Parallel Assignment

There is one SNP


1 L858R

exon 19 deletion or exon 21 L858R) 10. --- L858R ---

HPO Nodes